STOCK TITAN

[Form 4] ROCKET PHARMACEUTICALS, INC. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rocket Pharmaceuticals (RCKT) reported insider transactions. A company officer sold an aggregate 28,918 shares of common stock on 10/14/2025 across multiple trades priced between $3.96 and $3.975 per share. Following these sales, the officer beneficially owned 67,006 shares, held directly. The reporting person is identified as Vice President of Finance, Treasurer, and Principal Accounting Officer. Holdings noted include RSUs that convert to common stock on a one-for-one basis.

Rocket Pharmaceuticals (RCKT) ha riferito operazioni riservate. Un dirigente dell'azienda ha venduto in totale 28.918 azioni ordinarie il 14/10/2025 tramite più operazioni, a prezzi tra 3,96 e 3,975 USD per azione. Dopo queste vendite, l'ufficiale deteneva beneficialmente 67.006 azioni, possedute direttamente. La persona che segnala è identificata come Vice Presidente Finanza, Tesoriere e Responsabile principale della contabilità. Le partecipazioni indicate includono RSU che si trasformano in azioni ordinarie su base 1:1.

Rocket Pharmaceuticals (RCKT) reportó transacciones de insiders. Un directivo de la empresa vendió un total de 28,918 acciones ordinarias el 14/10/2025 a través de múltiples operaciones a un precio entre 3,96 y 3,975 dólares por acción. Después de estas ventas, el directivo poseía beneficiosamente 67,006 acciones, de forma directa. La persona informante se identifica como Vicepresidente de Finanzas, Tesorero y Responsable Principal de Contabilidad. Las participaciones señaladas incluyen RSU que se convierten en acciones ordinarias en una base 1 a 1.

Rocket Pharmaceuticals(RCKT)은 내부자 거래를 보고했습니다. 회사 임원이 2025년 10월 14일에 여러 건의 거래로 주당 3.96달러에서 3.975달러 사이의 가격으로 합산 28,918주를 매도했습니다. 이 매도 후 임원은 직접 보유한 67,006주를 보유하게 되었습니다. 보고자는 재무 부사장, 재무담당 이사 및 주 회계 책임자로 식별됩니다. 명시된 보유 주식에는 1대 1로 주식으로 전환되는 RSU가 포함되어 있습니다.

Rocket Pharmaceuticals (RCKT) a signalé des transactions d'initiés. Un dirigeant de l'entreprise a vendu au total 28 918 actions ordinaires le 14/10/2025 lors de plusieurs transactions à un prix compris entre 3,96 et 3,975 dollars par action. Suite à ces ventes, le dirigeant détenait bénéficiellement 67 006 actions, détenues directement. La personne déclarant est identifiée comme Vice-président des finances, trésorier et responsable principal de la comptabilité. Les détentions notées comprennent des RSU qui se convertiront en actions ordinaires sur une base 1 pour 1.

Rocket Pharmaceuticals (RCKT) meldete Insider-Geschäfte. Ein Unternehmensbeamter verkaufte am 14.10.2025 insgesamt 28.918 Stammaktien in mehreren Transaktionen zu Preisen zwischen 3,96 und 3,975 USD pro Aktie. Nach diesen Verkäufen besaß der meldende Beauftragte beneficial Ownership 67.006 Aktien, direkt gehalten. Die meldende Person wird identifiziert als Vizepräsident Finanzen, Schatzmeister und Principal Accounting Officer. Die gehaltenen Positionen umfassen RSUs, die eins zu eins in Stammaktien umgewandelt werden.

أعلنت Rocket Pharmaceuticals (RCKT) عن معاملات داخلية. باع أحد مسؤولي الشركة ما مجموعه 28,918 سهماً من الأسهم العادية في 14/10/2025 عبر عدة صفقات بسعر يتراوح بين 3.96 و3.975 دولاراً للسهم. عقب هذه المبيعات، امتلك المسؤول بشكل مفيد 67,006 أسهم، مملوكة بشكل مباشر. الشخص المبلّغ عنه مُعرَّف بأنه نائب رئيس المالية، أمين الخزانة، وكبير موظفي المحاسبة. تشمل الحيازات المذكورة RSUs التي تتحول إلى أسهم عادية بنسبة 1:1.

Rocket Pharmaceuticals (RCKT) 报告了内幕交易。 一名公司高管在 2025/10/14 通过多笔交易以每股 3.96 美元至 3.975 美元之间的价格累计卖出 28,918 股普通股。完成这些出售后,该高管直接持有 67,006 股。报告人被认定为财务副总裁、出纳以及首席会计官。所述持股包括可在 1:1 基础上转换为普通股的 RSU。

Positive
  • None.
Negative
  • None.

Rocket Pharmaceuticals (RCKT) ha riferito operazioni riservate. Un dirigente dell'azienda ha venduto in totale 28.918 azioni ordinarie il 14/10/2025 tramite più operazioni, a prezzi tra 3,96 e 3,975 USD per azione. Dopo queste vendite, l'ufficiale deteneva beneficialmente 67.006 azioni, possedute direttamente. La persona che segnala è identificata come Vice Presidente Finanza, Tesoriere e Responsabile principale della contabilità. Le partecipazioni indicate includono RSU che si trasformano in azioni ordinarie su base 1:1.

Rocket Pharmaceuticals (RCKT) reportó transacciones de insiders. Un directivo de la empresa vendió un total de 28,918 acciones ordinarias el 14/10/2025 a través de múltiples operaciones a un precio entre 3,96 y 3,975 dólares por acción. Después de estas ventas, el directivo poseía beneficiosamente 67,006 acciones, de forma directa. La persona informante se identifica como Vicepresidente de Finanzas, Tesorero y Responsable Principal de Contabilidad. Las participaciones señaladas incluyen RSU que se convierten en acciones ordinarias en una base 1 a 1.

Rocket Pharmaceuticals(RCKT)은 내부자 거래를 보고했습니다. 회사 임원이 2025년 10월 14일에 여러 건의 거래로 주당 3.96달러에서 3.975달러 사이의 가격으로 합산 28,918주를 매도했습니다. 이 매도 후 임원은 직접 보유한 67,006주를 보유하게 되었습니다. 보고자는 재무 부사장, 재무담당 이사 및 주 회계 책임자로 식별됩니다. 명시된 보유 주식에는 1대 1로 주식으로 전환되는 RSU가 포함되어 있습니다.

Rocket Pharmaceuticals (RCKT) a signalé des transactions d'initiés. Un dirigeant de l'entreprise a vendu au total 28 918 actions ordinaires le 14/10/2025 lors de plusieurs transactions à un prix compris entre 3,96 et 3,975 dollars par action. Suite à ces ventes, le dirigeant détenait bénéficiellement 67 006 actions, détenues directement. La personne déclarant est identifiée comme Vice-président des finances, trésorier et responsable principal de la comptabilité. Les détentions notées comprennent des RSU qui se convertiront en actions ordinaires sur une base 1 pour 1.

Rocket Pharmaceuticals (RCKT) meldete Insider-Geschäfte. Ein Unternehmensbeamter verkaufte am 14.10.2025 insgesamt 28.918 Stammaktien in mehreren Transaktionen zu Preisen zwischen 3,96 und 3,975 USD pro Aktie. Nach diesen Verkäufen besaß der meldende Beauftragte beneficial Ownership 67.006 Aktien, direkt gehalten. Die meldende Person wird identifiziert als Vizepräsident Finanzen, Schatzmeister und Principal Accounting Officer. Die gehaltenen Positionen umfassen RSUs, die eins zu eins in Stammaktien umgewandelt werden.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Militello John

(Last) (First) (Middle)
C/O ROCKET PHARMACEUTICALS, INC.
9 CEDARBROOK DRIVE

(Street)
CRANBURY NJ 08512

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
10/14/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock(1) 10/14/2025 S 19,841 D $3.96 76,083 D
Common Stock(1) 10/14/2025 S 5,514 D $3.965 70,569 D
Common Stock(1) 10/14/2025 S 3,005 D $3.97 67,564 D
Common Stock(1) 10/14/2025 S 558 D $3.975 67,006 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
Remarks:
Vice President of Finance, Treasurer, Principal Accounting Officer
/s/ Martin Wilson, as attorney-in-fact for John Militello 10/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Rocket Pharmaceu

NASDAQ:RCKT

RCKT Rankings

RCKT Latest News

RCKT Latest SEC Filings

RCKT Stock Data

431.62M
103.77M
3.27%
90.63%
14.35%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK